Generic Drug Bioequivalence Study Interruptions Not Just A Coronavirus Problem

 
• By Derrick Gingery

US FDA should create a policy to help save troubled studies, because failure can kill generic development programs, Lachman Consultants’ Michelle Ryder suggests.

PCR strip test tubes and micropipette in genetics laboratory. Toned photo
Generic drug sponsors are looking for help from the FDA to "save" bioequivalence studies interrupted by coronavirus or other problems. • Source: Shutterstock

More from Generics

More from Biosimilars & Generics